HRMY
$28.37
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
Recent News
Deutsche Bank Cuts PT on Harmony Biosciences Holdings (HRMY) to $30 From $31
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best cheap biotech stocks to buy now. On February 25, Deutsche Bank adjusted the price target on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) to $30 from $31 and reiterated a Hold rating on the shares, updating its model on the stock post the fiscal Q4 report. Harmony […]
Harmony Biosciences Downgrades Put Wakix Patent Risks In Sharp Focus
Harmony Biosciences Holdings (NasdaqGM:HRMY) is facing multiple broker downgrades after unfavorable comments in the Wakix patent trial. Analysts have raised concerns about increased risk of generic competition and the strength of the company’s intellectual property protection around Wakix. The judge’s remarks in the recent bench trial have introduced fresh uncertainty around future exclusivity for Wakix, Harmony’s key revenue driver. The market reaction has been sharp, with Harmony...
Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is among the 20 Best Investments in 2026. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best investment stocks on our list. TheFly reported on February 20 that Truist Securities downgraded HRMY from Buy to Hold following the conclusion of its bench trial against Paragraph IV filer AET Pharma. The analyst pointed […]
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y
Beam Therapeutics posts a narrower Q4 loss as revenues surge past estimates. It secures $500M financing, extending its cash runway into mid-2029.
IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress
Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.